In models of chronic myeloid leukemia, imatinib has been shown to inhibit vascular endothelial growth factor (VEGF) transcription, through Sp1 and Sp3 transcription factors (64). Here, VEGFA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.